Pharmacopeia
Master Compare
Compare candidate-facing canonical Pharmacopeia fields side by side. Isolated AI-draft proposals are never included.
| Field |
ACETAZOLAMIDE
Renal · Renal · Level 3
|
HYDROCHLOROTHIAZIDE
Renal · Renal · Level 3
|
|---|---|---|
| Mechanism of action | Diuresis |
inhibit Na+ reabsorption in the early portion of the distal tubule by |
| Physiological effects | Metabolic: Acidosis via ↑ excretion of bicarb (and reabsorption of Cl) |
Anti-HTN: (↓TPR, ↓plasma volume) |
| Absorption | IV/PO |
PO- BA ~50-80%. Onset 2hrs Dur 6-12hrs. |
| Distribution | Lip sol: crosses BBB |
— |
| Protein binding | 70-90% |
68% |
| Volume of distribution | — | 3.6-7.8L/kg |
| Metabolism | Not metabolised |
Not metabolized |
| Excretion | Unchanged in urine |
Urine (unchanged) |
| Half-life | 6-9hrs |
5.6-14.8hrs |
| Adverse Effects Toxicity | metabolic acidosis, urinary alkalinisation, parathesias, fatigue, Tox: Rashes, renal stones |
↓K+/Na+/Mg++, ↑Ca++/urea/glu/chol. |
| Class Group | Diuretic – Carbonic Anhydrase Inhibitor |
Diuretic - Thiazide |
| Indications Uses | Glaucoma |
heart failure and hypertension. Used in combination. mostly bound to plasma prot, and gain access to the tubule via secretion in the PCT. |
| Introduction | Sulfonamide |
related to the sulphonamides |
| Legacy Cicm Level | Level 3 |
Level 3 |
| Presentation | 250mg white tablets |
orange scored tablets of 25mg and combos |
| Route And Dose | 250-1000mg q6hrly |
PO. 12.5-200mg/day |